MAPK3 and drug-induced dyskinesia: Orofacial abnormal involuntary movements, L-DOPA-induced dyskinesia, and L-DOPA-induced dyskinesia markers such as p-ERK1/ 2, p-AcH3, and inflammatory markers such as COX-2 and NF-κB were all reduced by the combination treatment (Table 3).